Plasmin generation and fibrin(ogen)olysis following desmopressin infusion

Desmopressin acetate (DDAVP) is known to stimulate the release of tissue‐type plasminogen activator (t‐PA) from endothelial cells, but it is unclear whether the increased t‐PA actually elicits the plasmin generation and fibrin(ogen)olysis in the circulating blood. We measured plasma levels of plasmin‐α2‐plasmin inhibitor complex, fibrinogen degradation products (FgDP) and fibrin degradation products (FbDP) following desmopressin infusion in 19 patients with bleeding disorders or thrombophilia. Administration of desmopressin (0.3–0.4 μg/kg) produced a 4.0‐fold increase in plasmin‐α2‐plasmin inhibitor complex at 30 min, whereas neither FgDP nor FbDP was elevated significantly. These findings indicate that desmopressin infusion provokes the generation of plasmin in vivo, but most of the plasmin generated is complexed to α2‐plasmin inhibitor and does not degradate fibrin or fibrinogen.

[1]  H. Niwano,et al.  Fibrinolysis and Fibrinogenolysis in Disseminated Intravascular Coagulation , 1990, Thrombosis and Haemostasis.

[2]  A. Yoshikawa,et al.  Thrombin and plasmin generation in patients with liver disease , 1989, American journal of hematology.

[3]  P. Mannucci.  Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. , 1988, Blood.

[4]  W. Nieuwenhuizen,et al.  A Monoclonal Antibody-Based Enzyme Immunoassay for Fibrin Degradation Products in Plasma , 1988, Thrombosis and Haemostasis.

[5]  S. Lethagen,et al.  Intranasal and Intravenous Administration of Desmopressin: Effect on F VIII/vWF, Pharmacokinetics and Reproducibility , 1987, Thrombosis and Haemostasis.

[6]  N. Egberg,et al.  A pilot study; desmopressin (DDAVP) in the treatment of deep venous thrombosis. , 1987, Thrombosis research.

[7]  W. Nieuwenhuizen,et al.  A Quantitative Enzyme Immunoassay for Primary Fibrinogenolysis Products in Plasma , 1987, Thrombosis and Haemostasis.

[8]  J. Mimuro,et al.  Monoclonal antibodies to discrete regions in alpha 2-plasmin inhibitor. , 1987, Blood.

[9]  N. Aoki.  Fibrinolysis: Its initiation and regulation , 1986 .

[10]  A. Skjennald,et al.  Venous Thrombosis Following Diagnostic Transvenous Catheterization by Percutaneous Catheter Insertion: An Evaluation of Desmopressin as a Thromboprophylactic Agent , 1984, Thrombosis and Haemostasis.

[11]  J. Verheijen,et al.  Masking of Fibrinolytic Response to Stimulation by an Inhibitor of Tissue-Type Plasminogen Activator in Plasma , 1984, Thrombosis and Haemostasis.

[12]  R. Bertina,et al.  The Use of Desmopressin Acetate (DDAVP) as a Test of the Fibrinolytic Capacity of Patients – Analysis of Responders and Non-Responders , 1982, Thrombosis and Haemostasis.

[13]  N. Sakuragawa,et al.  Properties of the factor VIII after DDAVP (1-deamino-8-D-arginine vasopressin) infusion in normal subjects. , 1980, The Tohoku journal of experimental medicine.

[14]  P. Mannucci,et al.  Plasminogen activator response after DDAVP: a clinico-pharmacological study. , 1980, Thrombosis research.

[15]  D. Collen.  On the Regulation and Control of Fibrinolysis , 1980, Thrombosis and Haemostasis.

[16]  C. Prowse,et al.  Specificity in the Factor VIII Response to Vasopressin Infusion in Man , 1979, British journal of haematology.

[17]  B. Wiman,et al.  Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma. , 1979, Blood.

[18]  P. Mannucci,et al.  Studies on the prolonged bleeding time in von Willebrand's disease. , 1976, The Journal of laboratory and clinical medicine.

[19]  D. Collen,et al.  Measurement of free, one-chain tissue-type plasminogen activator in human plasma with an enzyme-linked immunosorbent assay based on an active site-specific murine monoclonal antibody. , 1987, Blood.

[20]  W. Nieuwenhuizen,et al.  New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody. , 1987, The Journal of laboratory and clinical medicine.